A Double-Function of PD-ECGF/TP Protein that Predict Response to Target Chemotherapy

Borzenko BG*, Bakurova EM and Mironova KA
Department of Biochemistry, Maksim Gorky National Medical University, Donetsk 83003, Ukraine

Abstract
High mortality rate of Ebola infections and less therapeutic options baffle the worldwide scientists and hamper the medical capability against disease spreads or disease-induced deaths and our understanding into this deadest virus.

This article is to outline multi-facet factors of causing Ebola epidemics and further discuss several pathways to update present medical capabilities worldwide and solve this enigma forever.

Introduction
The intensity of cellular DNA synthesis and, thus, cell division, depends on the level of the deoxythymidine triphosphatase (dTTP), the key precursor for DNA synthesis. In human body dTTP is synthesized following one of the two possible pathways. They are both "de novo" synthesis from simple precursors: NH3, CO2, amino acids and "salvage pathway" from thymine and thymidine, create dTTP, which can be reincorporated into DNA. Thymidine phosphorylase (TP, EC 2.4.2.4) is one from the key regulatory enzymes of "salvage pathway". TP first described in mammalian tissue in 1953 and then purified of plant, animal and bacterial sources [1,2]. This enzyme catalyses phosphorylization of the nucleosidic linkage of pyrimidine-2-deoxynucleosides with the formation of the thymine and deoxyribose (Figure 1).

Numerous immunohistochimical and TP-enzyme activity studies have shown that TP participates in many pathological and non-pathological processes. In main metabolic function appears to be catabolic, although some bacteria and tumors utilize the reverse reaction anabolically under stress of certain genetic or dietary deficiency. The catabolic function of TP is also suggested that the enzymatic activity is inhibited by thymine and enhanced by thymidine. The biochemical characterization of TP demonstrated that the enzyme has a low substrate specificity being able to recognize not only thymidine but also deoxyxypirimidine [3] and some pyrimidine analogs [4-6]. Besides, recent studies have suggested, that TP plays a key role in maintaining the balance of the nucleoside pool and controlling nucleic acid gomeostasis, by ensuring the correct supply of deoxyribonucleoside triphosphates (dNTPs) for DNA replication and repair [7].

Various kinds of solid tumors express TP and high TP-activity is correlated with micro vessel density. A recent study has reported that TP enhances interleukin-8 (IL-8) expression [8] and various inflammatory cytokines, such as tumor necrosis factor α (TNF-α) interleukin 1α (IL-1α) and interferon γ (IFN-γ).

IFN-γ most effectively increased the expression of TP in cultured human monocyctic cells [9]. Nevertheless, how TP expression is up-regulated in human tumors is still unclear.

In 1987 a novel angiogenic factor was investigated in platelet lysate [10], which was thought to be a classic growth factor, that binds its cell receptor to exert angiogenetic activity. This factor was named platelet-derived endothelial cell growth factor (PD-ECGF). In 1992, during the characterization of different variants of PD-ECGF transcripts, Usaka and colleagues observed that the amino acid sequence of human PD-ECGF is homologues to that of E. coli thymidine phosphorylase and reported, that PD-ECGF had additional structural and biochemical similarities with TP among which is TP activity [11]. Sequence analysis of the gene revealed a stretch of 120 amino acid to be identical to TP. Spraggon G, [12] based upon the already published three-dimensional-structure of TP [13] and the biochemical and biophysical similarities between PD-ECGF and TP [14] suggested that human PD-ECGF be same as human TP. How does TP induce angiogenesis? There are a lot of facts and a lot of hypothesis. It has been observed that TP strongly induces revascularization and plays an important role in angiogenesis, tumor growth, invasion and metastasis. Deoxy-D-ribose (DR) one of the degradation products of thymidine generated by TP activity has both angiogenic and chemotactic activity [15]. Both DR and TP inhibit a hypoxia-induced apoptotic pathway [16]. These findings suggest that DR is a downstream mediator of TP function. 2-deoxy-D-ribose, a stereoisomer of DR inhibits the promotion of angiogenesis, tumor growth and metastasis by TP [17,18]. Recent evidence suggests that DR effects endothelial cell migration though activation of the integrin downstream signaling pathway. It was known that DR may be an important energy source under hypoxic conditions. Many reports suggest that TP privotal for tumor progression [19].

Conclusion
In conclusion, PD-ECGF/TP has been found to have higher expression in tumor tissue compared to normal tissues in a variety of human malignancies and its expression is not only found in cancer cells but also in the stromal macrophages, lymphocytes and fibroblasts. Overall a higher level of PD-ECGF/TP expression is correlated with more metastasis and it appears to be a poor prognostic factor [21-24].

The disease in which an elevated of PD-ECGF/TP has been described thus far are immune system related and have features of chronic inflammation. Elevated levels of PD-ECGF/TP were found in rheumatoid arthritics patients. In another study it was shown that the expression of thymidine kinase (TK) and thymidine phosphorylase-TP as they relate to proliferation (Ki-67 labeling index) and angiogenesis

*Corresponding author: Borzenko BG, Department of Biochemistry, Maksim Gorky National Medical University, Donetsk 83003, Ukraine, Tel: 67- 621-25-75; E-mail: borzenko.bg@rambler.ru

Received June 04, 2015; Accepted June 09, 2015; Published June 11, 2015

Citation: Borzenko BG, Bakurova EM, Mironova KA (2015) A Double-Function of PD-ECGF/TP Protein that Predict Response to Target Chemotherapy. Metabolomics 5: e136. doi:10.4172/2153-0769.1000e136

Copyright: © 2015 Borzenko BG et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
(CD-31-stained blood vessels) in a series of 110-small cell lung cancer (NSCLC) tumors. Tumor size was not found to be associated with TK, TP, Ki-67. These findings provide additional evidence for the role of thymidine metabolism in the complex interaction of proliferation and angiogenesis [22].

Recent studies have suggested that direct 5-Fluorouracil (FUrA) anabolism to active Fur/UMP through the DNA pathway could result in high drug efficacy and demonstrated that TP was the limiting step of FUra tumoral activation following the DNA pathway yielding tumoral TP activity could therefore enhance drug response by augmenting the direct formation of the active metabolite Flu/UMP [23,24]. Since last century the 5-Fu with other anticancer agents and prodrugs from group of fluoropyrimidine are widely used. These drugs provide the basis for neoadjuvant chemotherapy in combination with various types of surgical procedures and different methods of polychemotherapy (endolymphatic and intra-arterial chemotherapy). Although our results [24] and many reports from other laboratories suggest that TP is pivotal for tumor progression and may be used for diagnosis and treatment of oncology patients.

We have also provided that TP activity changes in the blood serum of patients with gastric cancer demonstrate their activity peculiarities in tissues. Thus far, we have not direct proof of the presence of isoenzyme forms of TP, but different localization in the cytosol and in the nucleus is known to be capable of isoenzymes. Our results raise the possibility that the control of individual dynamics of TP activity in blood serum of gastric cancer patients may be useful as information tool for monitoring of patients and treatment optimization [24].

Finally, TP can also play a role in chemotherapy, since it is involved in the metabolism and degradation of several nucleoside analogs. In the light of the important role by TP activity both in tumor angiogenesis and in the synthesis of anticaner drugs, the ways for the discovery and the development of novel TP properties and inhibitors.

References

1. Friedkin M, Roberts D (1954) The enzymatic synthesis of nucleosides thymidine phosphorylase in mammalian tissue. J Biol Chem 207: 245-256.
2. Focher F, Spadari S (2001) Thymidine phosphorylase: a Two-face Janus in anticancer chemotherapy. Curr Cancer Drug Targets 1: 141-153.
3. Desgranges C, Razaka G, Raband M, Bricand H (1981) Catabolism of thymidine in human blood platelets. Purification and properties of thymidine phosphorylase. Biochem Biophys Acta 654: 211-218.
4. Piper AA, Fox RM (1982) Biochemical basis for the differential sensitivity of viral and cellular target-enzymes. Biochem J 351: 319-326.
5. Kornberg A, Baker T (1991) A DNA replication. Freeman and Co: New York.
6. Tabata S, Ikeda R, Yamamoto M, Furukawa T, Kuramoto T et al. (2012) Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells. Oncol Rep 38: 895-902.
7. Goto H, Kohn K, Sone S, Akiyama S, Kuwano M et al.(2001) Interferon-gamma-dependent induction of thymidine phosphorylase: platelet-derived endothelial growth factor through gamma-activated sequence - like element in human macrophages. Cancer Res 61: 469-473.
8. Miyazono K, Okabe T, Urabe A, Takaku F, Heldin CH (1987) Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 262: 4098-4103.
9. Verri A, Focher F, Duncombe RL, Basnak I, Walker RT et al. (2000) Anti-herpes Vimpex virus activity of 4-thio-2-deoxyuridines: A. biological investigation for viral and cellular target-enzymes. Biochem J 351: 319-326.